Neuropeptide W-23 (human)是Neuropeptide W的活性形式，由23个氨基酸组成，是GPR7和GPR8的内源性配体。
Cas No.:383415-79-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Neuropeptide W-23 (human), the active form of Neuropeptide W with a 23-amino acid peptide, is an endogenous ligand for GPR7 and GPR8 [1]. Neuropeptide W-23 can stimulate the release of prolactin and alter the release of growth hormone and adrenocorticotropic hormone (ACTH) [2]. Neuropeptide W-23 has been widely used to regulate the mean arterial pressure of awake rats and to control the feeding behavior of animals[3].
In vitro, Neuropeptide W-23 (400ng/ml) treatment for 24 hours significantly promoted the proliferation of ATDC5 cells and increased the phosphorylation levels of protein kinase A (PKA), PKCδ, p38, and ERK1/2 [4]. Treatment with 100nM Neuropeptide W-23 for 2 hours significantly inhibited the secretion and expression of leptin in rat adipocytes, and stimulated lipolysis [5].
In vivo, Neuropeptide W-23 treatment via continuous intraventricular injection at a dose of 3nmol (dissolved in 10μl 0.9% saline) daily for 1 week significantly reduced the food intake and body weight of Wistar rats, and increased body temperature and promoted heat production[6]. A single intrathecal injection of 10μg dose of Neuropeptide W-23 significantly reduced the mechanical allodynia in rats within 90 minutes[7].
References:
[1] Ji L, Zhu H, Chen H, et al. Modulation of CaV1. 2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7[J]. Journal of hypertension, 2015, 33(12): 2431-2442.
[2] Takenoya F, Kageyama H, Hirako S, et al. Neuropeptide w[J]. Frontiers in endocrinology, 2012, 3: 171.
[3] Pate A T, Yosten G L C, Samson W K. Neuropeptide W increases mean arterial pressure as a result of behavioral arousal[J]. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2013, 305(7): R804-R810.
[4] Wang R K, Zheng C, Jiang W, et al. Neuropeptide W regulates proliferation and differentiation of ATDC5: Possible involvement of GPR7 activation, PKA and PKC‐dependent signalling cascades[J]. Journal of Cellular and Molecular Medicine, 2019, 23(3): 2093-2102.
[5] Skrzypski M, Pruszyńska-Oszmałek E, Ruciński M, et al. Neuropeptide B and W regulate leptin and resistin secretion, and stimulate lipolysis in isolated rat adipocytes[J]. Regulatory Peptides, 2012, 176(1-3): 51-56.
[6] Naso T, Shousha S, El‐Kirdasy A. Central neuropeptide W has anorexigenic effect in rats[J]. Journal of animal physiology and animal nutrition, 2014, 98(2): 228-234.
[7] Yamamoto T, Saito O, Shono K, et al. Effects of intrathecal and icv administration of neuropeptide W-23 and neuropeptide B on the mechanical allodynia induced by partial sciatic nerve ligation in rats[J]. Neuroscience, 2006, 137(1): 265-273.
Neuropeptide W-23 (human)是Neuropeptide W的活性形式，由23个氨基酸组成，是GPR7和GPR8的内源性配体[1]。Neuropeptide W-23可刺激催乳素释放，改变生长激素和促肾上腺皮质激素的释放[2]。Neuropeptide W-23已被广泛用于调节清醒大鼠的平均动脉压以及控制动物的摄食行为[3]。
在体外，400ng/ml的Neuropeptide W-23处理ATDC5细胞24小时，显著促进了细胞增殖，并增加了protein kinase A (PKA)、PKCδ、p38和ERK1/2的磷酸化水平[4]。100nM的Neuropeptide W-23处理大鼠脂肪细胞2小时，显著抑制了瘦素的分泌和表达，并刺激了脂肪分解[5]。
在体内，每日持续脑室内注射3nmol（溶于10µl 0.9%生理盐水）的Neuropeptide W-23，持续1周，显著减少了Wistar大鼠的食物摄入和体重，并增加了体温，促进了产热[6]。单次鞘内注射10µg剂量的Neuropeptide W-23，在90分钟内显著减轻了大鼠的机械性痛觉超敏[7]。
| Cell experiment [1]: | |
Cell lines | ATDC5 cells |
Preparation Method | ATDC5 cells were cultured in 1:1 mixed DMEM and Ham'sF-12 media containing 10% fetal bovine serum, 100units/ml penicillin and 100μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2. ATDC5 cells were seeded in 96-well plates at the density of 1000 cells per well with 100μl of culture medium in the 5% (v/v) Fetal Bovine Serum (FBS) culture medium. After adhesion for 24 hours, the medium was changed to serum-free and Neuropeptide W-23 was added to medium with final concentrations (25, 50, 100, 200, and 400ng/ml), then the cells were re-cultured for 24 hours. The cells which were not exposed to Neuropeptide W-23 were used as controls. The wells with only culture medium served as blanks. ATDC5 cell proliferation was determined. |
Reaction Conditions | 25, 50, 100, 200, and 400ng/ml; 24h |
Applications | Neuropeptide W-23 treatment significantly enhanced cell proliferation of ATDC5 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | Male Wistar rats (weighing 250-300g) were housed in large polycarbonate maternity cages on ventilated racks at 22-23°C and kept under a 12:12 light/dark cycle. Food and water were freely available. Rats were anesthetized by intraperitoneal injection of sodium pentobarbital (45mg/kg). A stainless-steel cannula (guide cannula, 23 gauge; insert, 27 gauge; outer diameter, OD: 550μm) was then implanted into the lateral left ventricle. The cannula tip was placed at stereotaxic coordinates: 8mm anterior to interaural; 1.5mm lateral to the midline; 3.0mm below the dura. The guide cannula was anchored to the skull with machine screws and dental acrylic. After surgery, rats were housed individually and allowed to recover for 4 days before injection of Neuropeptide W-23. Rats were injected with saline before the study and were weighed and handled daily. Neuropeptide W-23 at a dose of 3nmol (dissolved in 10μl 0.9% saline) for 1 week or saline was administered (i.c.v.) to Wistar rats (n=8). Feeding intake and cumulative body weight gain were measured every day at 08:00 for 1 week. |
Dosage form | 3nmol (10µl); once a day for 7 days; i.c.v. |
Applications | Neuropeptide W-23 treatment significantly decreased feeding intake and weight gain in rats. |
References: | |
| Cas No. | 383415-79-0 | SDF | |
| 别名 | NPW-23 | ||
| 化学名 | (6S,7Z,9S,10Z,12S,13Z,15S,16Z,18S,19Z,22Z,24S,25Z,27S,28Z,30S,31Z,34Z,36S,37Z,39S,40Z,42S,43Z,46Z,48S)-12-((1H-imidazol-5-yl)methyl)-6-((Z)-(((S)-1-((2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S)-11-((1H-imidazol-5-yl)methyl)-20-amino-14-(4-aminobutyl)-4 | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])CC2=CNC3 | ||
| 分子式 | C119H183N35O28S | 分子量 | 2584.03 |
| 溶解度 | Soluble to 1 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 387 μL | 1.935 mL | 3.8699 mL |
| 5 mM | 77.4 μL | 387 μL | 774 μL |
| 10 mM | 38.7 μL | 193.5 μL | 387 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet